Home » Stocks » Eli Lilly

Eli Lilly and Company (LLY)

Stock Price: $152.93 USD 0.05 (0.03%)
Updated Aug 7, 2020 4:02 PM EDT - Market closed
After-hours: $152.88 -0.05 (-0.03%) Aug 7, 7:58 PM

Stock Price Chart

Key Info

Market Cap 146.27B
Revenue (ttm) 22.95B
Net Income (ttm) 5.62B
Shares Out 956.47M
EPS (ttm) 6.15
PE Ratio 24.87
Forward PE 22.42
Dividend $2.96
Dividend Yield 1.94%

Stock Quote

Trading Day Aug 7, 2020
Last Price $152.93
Previous Close $152.88
Change ($) 0.05
Change (%) 0.03%
Day's Open 152.89
Day's Range 151.58 - 153.50
Day's Volume 2,017,370
52-Week Range 101.36 - 170.75

More Stats

Market Cap 146.27B
Enterprise Value 160.21B
Earnings Date (est) Oct 27, 2020
Ex-Dividend Date May 14, 2020
Shares Outstanding 956.47M
Float 793.68M
EPS (basic) 6.19
EPS (diluted) 6.15
FCF / Share 5.76
Dividend $2.96
Dividend Yield 1.94%
Earnings Yield 4.02%
FCF Yield 3.57%
Payout Ratio 44.70%
Shares Short 5.23M
Short Ratio 1.39
Short % of Float 0.66%
Beta 0.22
PE Ratio 24.87
Forward PE 22.42
P/FCF Ratio 28.01
PS Ratio 6.37
PB Ratio 35.73
Revenue 22.95B
Operating Income 6.39B
Net Income 5.62B
Free Cash Flow 5.22B
Net Cash -13.94B
Net Cash / Share -14.57
Gross Margin 76.68%
Operating Margin 27.85%
Profit Margin 24.50%
FCF Margin 22.75%
ROA 9.90%
ROE 157.61%
ROIC 20.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 7
Overweight 0
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(13.95% upside)
Current: $152.93
Target: 174.27
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth3.84%7.61%-5.88%6.33%1.75%-15.13%2.25%-6.93%5.25%-
Gross Profit17,59816,81215,52615,51214,92214,68318,20517,80719,21918,710
Operating Income5,2663,6802,3053,3742,7903,0005,8895,4085,3506,525
Net Income8,3183,232-2042,7382,4082,3914,6854,0894,3485,070
Shares Outstanding9311,0281,0521,0581,0621,0701,0811,1131,1581,153
Earnings Per Share8.893.13-0.192.582.262.234.323.663.904.58
EPS Growth184.03%--14.16%1.35%-48.38%18.03%-6.15%-14.85%-
Dividend Per Share2.582.
Dividend Growth14.62%8.22%1.96%2%2.04%0%0%0%0%-
Operating Cash Flow4,8375,5255,6164,8512,9654,4585,7355,3057,2356,857
Capital Expenditures-1,034-1,211-1,077-964-974-1,147-833-883-647-670
Free Cash Flow3,8034,3144,5393,8871,9913,3114,9024,4216,5886,187
Cash & Equivalents2,4397,4098,0346,0394,45210,2335,3975,6846,8976,727
Total Debt15,31710,29913,64710,3057,9798,0225,2135,5316,9876,927
Net Cash / Debt-12,879-2,890-5,613-4,267-3,5272,211184153-89.90-200
Book Value2,6079,82911,59214,00814,57115,37317,63114,76513,53612,413
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Eli Lilly and Company
Country United States
Employees 34,720
CEO David A. Ricks

Stock Information

Ticker Symbol LLY
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: LLY


Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.